VistaGen Therapeutics, Inc. and Duke University Publish Results on Production of Functional 3D Human Heart Tissue
5/7/2013 10:32:15 AM
More...
|
VistaGen Therapeutics, Inc. Raises $36 Million
4/10/2013 7:21:28 AM
More...
|
VistaGen Therapeutics, Inc. to Present Enhancements and Expanded Validation of LiverSafe 3D™ at Society of Toxicology's 52nd Annual Meeting
3/12/2013 9:09:33 AM
More...
|
VistaGen Therapeutics, Inc. to Present CardioSafe 3D™ Developments at Society of Toxicology's 52nd Annual Meeting
3/11/2013 9:57:36 AM
More...
|
VistaGen Therapeutics, Inc. Enters Strategic Collaboration With Celsis In Vitro Technologies (CEL.L) to Further Advance LiverSafe 3D™
3/4/2013 9:44:26 AM
More...
|
VistaGen Therapeutics, Inc.'s Collaborators Identify Definitive Precursor for Adult Blood and the Immune System
2/7/2013 9:20:42 AM
More...
|
VistaGen Therapeutics, Inc. Successfully Completes Final Phase 1 Safety Study of AV-101
1/23/2013 9:20:32 AM
More...
|
VistaGen Therapeutics, Inc. to Present at Noble Financial Capital Markets Ninth Annual Equity Conference
1/22/2013 8:53:34 AM
More...
|
VistaGen Therapeutics, Inc. Becomes Member of Center for Commercialization of Regenerative Medicine (CCRM) Consortium
12/3/2012 12:09:58 PM
More...
|
VistaGen Therapeutics, Inc. and Duke University Announce Heart Tissue Engineering Progress at American Heart Association 2012 Scientific Sessions
11/7/2012 8:52:23 AM
More...
|
|